OClawVPS.com
Categories: CommerceEnergyTechEngineeringFutureHumanIndustryManufacturingMedtechProductTechnology
Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® platform to discover and develop novel, high performance enzymes and novel biotherapeutics.

Codexis enzymes have applications in the sustainable manufacturing of pharmaceuticals, food, and industrial products; in the creation of the next generation of life science tools; and as gene therapy and biologic therapeutics.

The Company’s unique performance enzymes drive improvements such as: reduced energy usage, waste generation and capital requirements; higher yields; higher fidelity diagnostics; and more efficacious therapeutics.

Codexis enzymes enable the promise of synthetic biology to improve the health of people and the planet.
Followers
3.72K
Website visits
24.6K /mo.
Mentions
62
Location: United States, California, Redwood City
Employees: 201-500
Total raised: $50M
Founded date: 2002

Investors 2

Funding Rounds 1

DateSeriesAmountInvestors
20.06.2019-$50MCasdin Cap...

Mentions in press and media 62

DateTitleDescription
10.09.2025Ridge Biotechnologies Raises $25M in Seed FinancingRidge Biotechnologies, a Palo Alto, CA-based company providing an enzyme and targeted drug design to improve the precision medicines, raised $25M in Seed funding. The round was led by Sutter Hill Ventures (SHV) with participation from Overl...
18.08.2025The Nomination Committee’s proposal for the annual general meeting in EQL Pharma ABThe Nomination Committee’s proposal for the annual general meeting in EQL Pharma AB Mon, Aug 18, 2025 11:00 CET Report this content Ahead of the annual general meeting on 21 August 2025 in EQL Pharma AB, the Nomination Committee has present...
08.08.2024Codexis Reports Second Quarter 2024 Financial ResultsCompany Reiterates Full-year Financial Guidance; On Track to Achieve Product Revenue Growth of at Least 10% vs. FY2023 Excluding Enzyme Sales Related to PAXLOVID™ Anticipate Entering First Technical Collaboration for ECO Synthesis™ Manufact...
11.06.2024Move over, GLP-1s. Syntis launches with clinical-stage obesity pill to mimic gastric bypass surgeryGLP-1 agonists and their next-gen successors may still be center stage in the red-hot obesity space, but newly launched Syntis Bio is taking a different approach. The Boston-based biotech’s lead program is called SYNT-101, a once-daily pill...
28.02.2024Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsAnticipate 2024 Product Revenue Growth of at Least 10% vs. 2023 Excluding Enzyme Sales Related to PAXLOVID™ Recently Announced Debt Financing Reinforces Strong Financial Position with Projected Runway Through Expected Positive Cash-flow Aro...
13.02.2024Codexis Secures $40 Million in Strategic Financing Deal with Innovatus Capital Partners to Further Strengthen Cash Position Ahead of Key Milestones-
17.11.2022Startup Cradle Lets You Design Custom Proteins By Just Typing In A PromptCradle Team at their site in the Netherlands.Cradle
04.11.2021The SynBio Innovation Accelerator, a Collaboration between Codexis and Casdin Capital, Enables $10 million Investment in Molecular Assemblies, Inc.Funding to accelerate MAI’s go-to-market strategy as the enzyme engineering phase nears completion Represents the second early-stage company investment enabled by the SynBio Innovation Accelerator REDWOOD CITY, Calif., Nov. 04, 2021 (GLOBE ...
27.09.2019How To Spot A Synthetic Biology UnicornBiotech is projected to reach $775 billion by 2024, but dozens of companies in the field of ... [+] synthetic biology are creating magical tools to go beyond that. Look here for the next unicorn. Jelena Trmčić for SynBioBeta
21.06.2019Codexis Receives $50M Investment from Casdin CapitalCodexis, Inc. (Nasdaq: CDXS), a Redwood City, Calif.-based synthetic biology company, received a $50 million investment from Casdin Capital, LLC. Casdin, a New York City-based life science-focused investment firm, has invested through the p...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In